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Endothelial  cell dysfunction  is a term  which  implies  the  dysregulation  of  normal  endothelial  cell func-
tions,  including  impairment  of  the barrier  functions,  control  of vascular  tone,  disturbance  of  proliferative,
migratory  and  morphogenic  capacities  of endothelial  cells,  as well  as  control  of  leukocyte  trafﬁcking.
MicroRNAs  are  short  non-coding  RNAs  that  have  emerged  as  critical  regulators  of  gene  expression  act-eywords:
ndothelial cells
icroRNAs
ascular disease
icroRNA therapeutics
ing  predominantly  at the  post-transcriptional  level.  This  review  summarizes  the  latest  insights in the
identiﬁcation  of endothelial-speciﬁc  microRNAs  and  their  targets,  as well as  their  roles  in controlling
endothelial  cell  functions  in both  autocrine  and  paracrine  manner.  In addition,  we discuss  the  therapeu-
tic  potential  for the  treatment  of  endothelial  cell dysfunction  and  associated  vascular  pathophysiological
conditions.ndothelial cell dysfunction © 2013 The Authors. Published by Elsevier Ltd. 
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The endothelium is the monolayer of endothelial cells (ECs)
lining the lumen of blood vessels in every organ system. These
cells function as a protective biocompatible barrier between all
tissues and the circulating blood [1]. ECs facilitate the bidirectional
passage of nutrient substances and active molecules from blood to
tissues, but also play a major role in controlling the passage of blood
cells themselves. ECs are specially designed and spatially located
to detect changes in hemodynamic forces and blood-borne signals.
icense.
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n addition, ECs regulate the release of a number of autocrine
nd paracrine factors in response to these signals to favor the
aintenance of vascular homeostasis [2–9]. Therefore, normal
C function is critical for all aspects of vascular homeostasis (i.e.
ontrol of blood vessel development, growth and differentiation;
ontrol of leukocyte trafﬁcking; control of vascular tone; con-
rol of vascular barrier; control of platelet function, coagulation
nd ﬁbrinolysis). These have been reviewed in depth elsewhere
2–4,6–8,10].
EC dysfunction disrupts the balance between vasoconstriction
nd vasodilation and initiates a number of events that trig-
er EC activation and predispose the vessel wall to increased
ndothelial permeability, leukocyte adherence, endothelial prolif-
ration, pro-oxidation and thrombosis [5,7,11–18]. Perturbations
n EC functions have been implicated in several diseases including
therosclerosis, diabetes, tumor metastasis, inﬂammatory dis-
ases (e.g. rheumatoid arthritis) and hypertension [5,12,16,19–21].
mportantly, the processes involved in EC activation require inte-
ration of the molecular and cellular events induced by both
timulatory and inhibitory signals. These include signal trans-
uction pathways leading to transcriptional regulation of gene
xpression programs, as well as post-transcriptional and post-
ranslational modiﬁcations that ﬁne-tune this response. In this
egard, microRNAs (miRNAs) have emerged as critical regulators of
ene expression, acting predominantly at the post-transcriptional
evel [22–25].
In the present review we summarize the latest insights in the
dentiﬁcation of endothelial-speciﬁc miRNAs and their targets, as
ell as their role in regulating EC functions both in an autocrine
nd paracrine fashion. In addition, we discuss their therapeutic
otential in the treatment of EC dysfunction and associated vascular
athophysiological conditions.
. MicroRNA biogenesis and function
MiRNAs are short noncoding RNAs that have emerged as crit-
cal regulators of gene expression acting predominantly at the
ost-transcriptional level [23,25]. According to the miRNA.org data
esource, as of April 2013, 1100 miRNAs have been annotated
n Homo sapiens and 717 in Mus  musculus [26], while MirBase
eports 2042 human and 1281 murine miRNAs [27,28]. Canon-
cally these small RNAs are transcribed by RNA polymerase II
rom individual miRNA genes, introns of protein coding genes, or
olycistronic transcripts as capped and polyadenylated primary
iRNA transcripts (pri-miRNA) [29,30]. Then the pri-miRNA is
rocessed in the nucleus into a ∼70-nucleotide precursor hair-
in (pre-miRNA) by ribonuclease III (RNase III), called Drosha in
ooperation with a dsRNA binding protein, DiGeorge syndrome
ritical region gene 8 (DGCR8) [31,32]. Additionally, there is a
roup of intronic miRNAs (miRtrons) that bypass the Drosha path-
ay and are produced by splicing and debranching [33]. The
ransport receptor Exportin-5, RanGTP-dependent dsRNA-binding
rotein, exports the pre-miRNAs to the cytoplasm [34], where
hey are further processed by the RNaseIII enzyme, Dicer, into an
pproximately 22 nt miRNA/miRNA* duplex [35,36]. Although the
iRNA/miRNA* duplex are produced in equal amounts by tran-
cription, the abundance of mature strands is asymmetric at the
teady state and it depends on the thermodynamic stability of the
′ end of the miRNA strand [37,38]. Usually the miRNA* strand
or passenger strand) is the least thermodynamically stable and
s rapidly degraded, however recent reports have shown that it
as well-conserved target recognition sites that are also functional
39,40].
Following processing, the selected miRNAs are incorporated
nto the RNA-induced silencing complex (RISC) [41,42] whichogical Research 75 (2013) 15– 27
mediates the miRNA binding to the 3′ untranslated regions (3′UTR)
of target messenger mRNA (mRNA) and negatively regulates gene
expression by translational inhibition or target mRNA degradation
or a combination of both [41,43,44]. In order to repress the tran-
script, it is crucial that the nucleotides in position 2–8 of the miRNA
(called the seed sequence) are almost perfectly complimentary to
regions at the 3′UTR of their target genes [45].
Computational predictions have revealed that 60% of protein-
coding genes harbor miRNA target sites in their 3′UTR [46] and that
a single miRNA can modulate the expression of hundreds genes. Not
only are certain miRNA genes highly conserved in animals, but their
target sites in the 3′UTR of genes are also under positive evolution-
ary selection. MiRNAs are powerful modulators of genetic networks
and they do so by acting both in a coherent and incoherent fash-
ion on their target genes [47,48]. MiRNAs, rather than functioning
as regulatory on-off switches, often function to modulate or ﬁne-
tune cellular phenotypes [24,49,50]. The deregulation of miRNA
expression could affect multiple cellular processes. Therefore it is
not surprising that miRNAs have been implicated in various pro-
cesses, from development to aging [24,49,50]. Additionally, many
miRNAs exhibit striking tissue speciﬁc expression patterns [51–56],
suggesting a cell type-speciﬁc function [51].
MiRNAs are necessary for development and organogenesis.
Loss of Dicer in mice results in embryonic lethality at E7.5 and
embryonic stem cells cannot be obtained from Dicer null mutants,
suggesting that Dicer is especially important in maintaining the
pluripotent status [57,58]. Also Ago loss gives rise to severe devel-
opmental defects by E10.5 [59]. At E11.5–E14.5 the developing
mouse embryo expresses Dicer1 and the Ago proteins only in
certain anatomical compartments and in a dynamic fashion, sug-
gesting a further role for miRNAs in organogenesis as well [60].
Given the essential role of the miRNA processing machinery in
development, it is not surprising that miRNAs have been shown
to be relevant in vascular development [51] and vascular functions
[61–67].
3. Control of blood vessel development, growth and
differentiation by endothelial microRNAs
The de novo generation and remodeling of blood vessels is essen-
tial for embryonic growth and throughout postnatal life. During
adulthood, the endothelium remains essentially quiescent to fulﬁll
its main function in conducting nutritive blood ﬂow to organs, with
turnover rates on the orders of months to years. Rapid changes in
EC proliferation rates occur following activation of the endothelium
by angiogenic cytokines [68–71]. In fact, in the healthy adult, angio-
genesis occurs only in select phases of the female reproductive cycle
and as a protection mechanism in wound healing/tissue repair and
is almost exclusively associated with pathology when angiogene-
sis is induced by micro-environmental factors such as hypoxia or
inﬂammation [68,70,72–75]. ECs play a key role in angiogenesis
which is dependent on the proliferation, migration and differenti-
ation of these cells [76].
The pathological processes associated with angiogenesis include
diseases as diverse as cancer, macular degeneration, psoriasis,
diabetic retinopathy, thrombosis, and inﬂammatory disorders,
including arthritis and atherosclerosis. Moreover, insufﬁcient
angiogenesis is characteristic of ischemic heart disease, periph-
eral vascular disease and pre-clampsia [68,69]. The above examples
represent the broad array of diseases that are associated with dys-
function of the angiogenic activated EC phenotype.The ﬁrst evidence of the importance of miRNAs in vascular
development was shown by Yang et al. who  generated a Dicer ex1/2
knockout mice, where Dicer was hypomorphic because of the dele-
tion of its ﬁrst and second exons. However, homozygous embryos
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ied between days E12.5 and E14.5 of impaired vascular forma-
ion and maintenance, showing that Dicer was essential for normal
ascular development [51]. Interestingly, the expression of vascu-
ar endothelial growth factor (VEGF) and the VEGF receptors, FLT1
nd VEGF receptor 2 (VEGFR2), was upregulated in mutant embryos
hile the expression of the angiopoietin receptor, Tie-1, was  lower
han wild type embryos, suggesting that the impaired angiogenesis
as due to the deregulation of these critical angiogenic regulators
51]. In the context of ECs, the knockdown of Dicer in vitro [77]
ndicated that miRNAs were important for regulating the angio-
enic functions of ECs. In fact, the silencing of Dicer modulated the
xpression of several proteins implicated in the control of vascular
one and angiogenesis (e.g. VEGFR2, TEK/Tie-2, interleukin 8 (IL)-8
nd endothelial nitric oxide synthase (eNOS) among others) and
mpaired EC proliferation and cord formation. Later Kuehbacher
t al. showed that the silencing of either Drosha or Dicer negatively
egulated the expression of miR-let7a and miR-27b while increased
he anti-angiogenic factor thrombospondin-1 (Tsp-1) [78]. In addi-
ion, the knockdown of Drosha and Dicer reduced sprout formation
78]. Finally, these results were conﬁrmed in vivo using EC-speciﬁc
icer knockout mice [79]. Although the inactivation of Dicer in the
ndothelium did not alter vascular development, it reduced the
ostnatal angiogenic response to multiple stimuli such as exoge-
ous VEGF or in models of tumorigenesis, limb ischemia and wound
ealing [79].
The aforementioned experimental approaches reveal the con-
equences of a block in miRNA biogenesis. However, the majority
ig. 1. Role of miRNAs in endothelial cell phenotype, functions and vascular disease and the
nd  atherosclerotic vascular disease, (C) vascular tone and endothelial cell barrier, and (Dogical Research 75 (2013) 15– 27 17
of these studies do not provide information regarding the functions
of speciﬁc miRNAs. Examples that illustrate the roles of individual
miRNAs in blood vessel development, growth and differentiation
are presented below and depicted in Fig. 1A.
MiR-126 is considered the prototype of an endothelial-speciﬁc
miRNA. It is highly expressed in vascularized tissues, ECs and
hematopoietic stem cells [79–84]. Interestingly, the miR-126 gene
is located within an intron of the epidermal growth factor-like-
domain 7 (EGFL7) gene, also known as Vascular Endothelial-statin
(VE-statin), which is mostly expressed in ECs and involved in
vascular tubulogenesis [85,86]. In contrast, the host gene EGFL7
is modestly expressed in mature vessels in normal adult tissue
and highly expressed in tumor endothelium [85,86]. The role of
miR-126 in vascular integrity and angiogenesis was  reported by
targeted deletion of miR-126 in mice [87,88] and its knockdown
in zebraﬁsh [89]. MiR-126 was shown to target sprouty-related
protein (SPRED1) and phosphoinositol-3 kinase regulatory subunit
2 (PIK3R2/p85-),  both negative regulators of the VEGF path-
way [87–89]. Additionally, miR-126 also enhanced Angiopoietin-1
(Ang-1) signaling through PIK3R2/p85- repression, implicating
that miR-126 is also involved in vessel stabilization and maturation
[90]. The miR-126/Egﬂ7 gene is transcriptionally regulated by Ets-1
and Ets-2 in ECs [82]. Recently, Nicoli et al. described a new mech-
anism for the regulation of miR-126 by blood ﬂow in zebraﬁsh. In
particular, blood ﬂow, through the mechanosensitive transcription
factor kruppel-like factor 2a (KLF2a), induced miR-126 expression,
which in turn activated the VEGF pathway [91]. Consistent with the
ir direct targets. MicroRNAs involved in: (A) angiogenesis, (B) vascular inﬂammation
) secreted microRNAs and biomarkers.
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ngiogenic properties of miR-126, Van Solingen et al. demonstrated
hat the use of antagomiR-126 impairs ischemia-induced angiogen-
sis [92]. Interestingly, the expression of miR-126 has been shown
o be downregulated in different cancers acting as a tumor sup-
ressor by inhibiting tumor growth [93–97]. Additionally, miR-126
epressed VEGF expression in lung cancer cells [98]. However, it
hould be considered that miR-126 regulates the EC response to
roangiogenic factors (e.g. VEGF and Ang-1) thus promoting angio-
enesis. Therefore, further analysis to elucidate the role of miR-126
n tumor vasculature is needed to ascertain whether miR-126 could
e a therapeutic tool to target tumor growth and angiogenesis.
As noted above, the relationship between miRNAs and their host
ene is especially relevant in miRNAs encoded within an angiogenic
ost gene. The highly conserved miR-218 is an intronic miRNA
ncoded within the Slit2 and Slit3 genes [99–101]. Slits are secreted
lycoproteins, which are the main ligands for Roundabout recep-
ors (Robos). Slit/Robo signaling is mediated by heparan sulfate
roteoglicans (HSPG), and regulates axon and vascular guidance.
mall et al. reported the relevance of miR-218 in the regulation
f Slit/Robo signaling through repression of Robo1, Robo2 and
lucuronyl C5-epimerase (GLCE), an enzyme involved in HSPG
iosynthesis [101]. Importantly, the silencing of miR-218 resulted
n abnormal EC migration and reduced complexity of the retinal
asculature [101]. Recently, Fish et al. reported that Slt2-Robo1-
iR-218 signaling is also required during heart development in
ebraﬁsh [99].
The miR-17-92 cluster is one of the best-characterized poly-
istronic miRNAs and is located in intron 3 of the C13orf25 gene
chromosome 13q31.3). MiR-17-92 encodes 6 individual miRNAs:
iR-17, miR-18a, miR-19a, miR-20a, miR-19b and miR-92a, which
re tightly grouped within an 800 base-pair region [102,103].
he miR-17-92 cluster is involved in cell proliferation, suppresses
poptosis of cancer cells, and induces tumor angiogenesis. The ﬁrst
vidence of the oncogenic role of miR-17-92 was suggested by the
mpliﬁcation of the genomic location corresponding to miR-17-92
n lymphoma and solid tumors [102,104]. MiR-17-92 is regulated
t the transcriptional level by the oncogenic transcription factor,
-Myc and its downstream effector E2F that promotes cell cycle
rogression [105]. MiR-17 and miR-20, which have identical seed
equences, repress E2F1, providing a tight regulation of c-Myc-
ediated cellular proliferation. In addition, the miR-17-92 cluster
s regulated by the c-Myc homologue MYCN in neuroblastoma, and
egulates cell cycle progression and apoptosis through repressing
21 and Bcl-2 interacting mediator of cell death (BIM) [106].
verexpression of the entire miR-17-92 cluster in Myc-induced
umors increases angiogenesis by a paracrine mechanism [107].
his pro-angiogenic function has been attributed to the downregu-
ation of anti-angiogenic proteins such as connective tissue growth
actor (CTGF) and Tsp-1, which are targeted by miR-18 and miR-19
79,107]. In addition, miR-17 also represses the anti-angiogenic
actor tissue inhibitor of metalloproteinase 1 (TIMP1) [108]. These
ndings were also conﬁrmed in the context of ECs, where the
ombined inhibition of miR-17, miR-18 and miR-20a reduced
roliferation and their overexpression rescued the decreased
orphogenic capacity of ECs induced by Dicer silencing [79].
nterestingly, these components of the miR-17-92 cluster (miR-17,
iR-18 and miR-20a) were induced upon VEGF treatment [79],
herefore indicating that these miRNAs contribute to promote
EGF-induced angiogenic responses. However, in another model
ystem, the overexpression of different components of miR-17-92,
n particular miR-17, -18a, -19a, and -20a, impaired sprouting
hereas their inhibition increased sprouting in ECs [109]. In this
ontext, miR-17 was shown to negatively regulate the expression
f the proangiogenic Janus kinase 1 (JAK1) [109], while miR-19a
as shown to modulate cell cycle progression by targeting cyclin
1 (CCND1) in ECs [110]. Additionally, overexpression of theogical Research 75 (2013) 15– 27
remaining member of the cluster, miR-92a, decreased sprouting
in vitro and also induced defects in intersegmental vessel for-
mation in zebraﬁsh [111]. Interestingly, miR-92a overexpression
reduced the expression of integrin subunits 5 (ITG5) and 
(ITG), of the sphingosine-1-phosphate receptor 1 (S1P1) and of
mitogen-activated kinase kinase 4 (MKK4) and eNOS in ECs [111].
The miR-106b-25 cluster, which is evolutionarily related to the
miR-17-92 cluster, is also involved in angiogenesis. A recent paper
from Semo et al. [112] revealed that absence of the cluster in a
model of hindlimb ischemia impaired the capacity of restoring nor-
mal  blood ﬂow and signiﬁcantly decreased capillary formation. This
effect was  attributed to the ability of the cluster to inhibit pro-
liferation, migration and viability in ECs. However, the targets of
miR-106b-25 responsible for this phenotype were not investigated.
The miR-23-24-27 cluster is expressed in ECs and vascular-
ized tissues and is heavily involved in angiogenesis There are two
miR-23-24-27 genes in mammals, an intergenic miR-23a–27a–24-
2 cluster (chromosome 9q22) and an intronic 23b–27b–24-1 cluster
(chromosome 19p13) [113]. This cluster mediates diverse process,
such as proliferation, cell cycle arrest, apoptosis and migration
[113]. Moreover, miR-23-24-27 has been involved in the regula-
tion of angiogenesis during vascular disorders and ischemic heart
disease [114,115], and their role has been elucidated in vitro and
in vivo [116]. In particular, miR-23 and miR-27 repress Sprouty2
(SPRY2) and Semaphorin-6A (SEMA6A), which negatively regulate
Ras/MAPK signaling and VEGFR2 mediated signaling, respectively
[114]. In agreement with these data, Urbich et al. showed that the
inhibition of miR-27a and miR-27b impairs sprouting in ECs in vitro
and embryonic vessel formation in zebraﬁsh through repression of
SEMA6A [117]. Importantly, in a murine model of laser-induced
choroidal neovascularization, the administration of locked nucleic
acid (LNA)-anti-miR-23/27 increased the expression of SPRY2 and
SEMA6A and impaired retinal vascular development [114]. The
other member of the cluster, miR-24, is highly expressed in cardiac
ECs and its expression increases in cardiac ischemia and in hypoxic
conditions [115]. MiR-24 overexpression enhanced endothelial
apoptosis and impaired angiogenesis by targeting the transcrip-
tion factor GATA2 and the p21-activated kinase (PAK4). MiR-24
overexpression, as well as knockdown of miR-24 targets, hindered
vascular development in zebraﬁsh, whereas endogenous inhibi-
tion of miR-24 by antagomirs enhanced angiogenesis and cardiac
function after myocardial infartion in mice [115]. Interestingly, the
expression of several members of the miR-23-24-27 cluster, in
particular miR-23b and miR-27, are upregulated by shear stress
and correlate with pulsatile shear (PS)-induced EC growth arrest.
Furthermore, the inhibition of miR-23b using antagomirs partially
rescued PS-induced growth arrest by an increase in the phosphor-
ylation of the retinoblastoma (Rb) protein [118].
3.1. MicroRNAs regulated by angiogenic factors: extinguishers or
igniters?
A ﬁne balance between positive and negative regulators
controls angiogenesis [68,72,75,119]. While there are many angio-
genic inducers, VEGF and basic ﬁbroblast growth factors (bFGF)
are probably the most critical and potent ones. The pro-angiogenic
effect of VEGF and bFGF is mediated through the VEGFR2, which
is selectively expressed in vascular ECs, or the FGF receptor 1
(FGFR1), respectively [72,120–123]. Activation of these receptors
stimulates the angiogenic cascade that leads to the degradation
of the extracellular matrix, migration to the perivascular space,
proliferation and formation of tubes [71,76]. MiRNAs do not only
control the angiogenic response, but their expression may  also be
regulated by pro-angiogenic factors (e.g. as introduced above for
the miR-17-92 cluster whose expression is regulated by VEGF to
promote the angiogenic response of ECs [79]). Some examples of
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icroRNAs regulated by angiogenic factors can be found below
nd are illustrated in Fig. 1A.
MiR-16 and miR-424 have been described to be anti-angiogenic
iRNAs because of their capability to repress VEGFR2, FGFR1 and
EGF in ECs [124]. Speciﬁcally, miR-16 or miR-424 overexpression
educes EC proliferation, migration, and impairs cord formation on
atrigel in vitro. Conversely, the endogenous inhibition of miR-16
nd miR-424 had opposite effect on these phenotypes. Importantly,
entiviral overexpression of miR-16 reduced blood vessel formation
n vivo. Interestingly, miR-16 and miR-424 are intriguing examples
f miRNAs whose expression is regulated by proangiogenic factors
uch as VEGF and bFGF at the transcriptional level [124]. Given their
egative effects on angiogenesis, their transcriptional regulation
pon angiogenic stimuli provides a negative feedback control of
ngiogenesis [124].
Another example of a miRNA regulated by pro-angiogenic fac-
ors that conversely has an angiogenic phenotype is miR-132. The
ndothelial miR-132 is an intergenic miRNA (chromosome 17)
nd its expression is regulated by the transcription factor cAMP
esponse element binding protein (CREB) [125,126]. Annand et al.
howed that miR-132 acts as a switch to induce neovasculariza-
ion by suppressing endothelial p120RasGAP expression, a GTPase
ctivating protein that attenuates p21 Ras activity [127]. MiR-
32 expression levels are undetectable in quiescent endothelium
hile it is highly expressed in endothelium in tumors and heman-
iomas [127]. Several pro-angiogenic factors, such as VEGF and
FGF, increased the expression of miR-132 through CREB activation
n ECs [127]. Overexpression of miR-132 increased proliferation
nd cord formation in ECs in vitro, whereas anti-miR-132 produced
 converse effect that was also observed in vivo by reducing both
evelopmental and pathological angiogenesis [127].
Interestingly, Dentelli et al. showed that interleukin 3 (IL)-3
nd bFGF negatively modulated the expression of miR-221/miR-
22 in ECs. Several studies have demonstrated that IL-3 and bFGF
re released by inﬁltrated T-lymphocytes in the atherosclerotic
laque, promoting neovascularization [128,129]. STAT5A, a tran-
cription factor that regulates the expression of genes involved
n cell proliferation and migration [128], was identiﬁed as tar-
et for miR-222 [130]. Interestingly, upregulation of STAT5A due
o IL-3/bFGF-induced down-regulation of miR-222 controled EC
roliferation and migration and therefore facilitated intraplaque
eovascularization during atherosclerosis. Moreover, in advanced
esions the authors found an increased proliferation rate of ECs
ining vessels, which correlated with a diminished expression of
iR-222 [130]. In line with these ﬁndings, Poliseno et al. previ-
usly reported that miR-221/miR-222 regulated proliferation and
igration through the regulation of c-kit in ECs [80]. On the other
and, miR-221 has been shown to inhibit angiogenesis by target-
ng zinc ﬁnger E-box binding homeobox 2 (ZEB2), a modulator
f the epithelial-mesenchymal transition, leading to decreased EC
roliferation [131]. Interestingly, miR-221/miR-222 repressed the
xpression of the transcription factor Ets-1, which regulates genes
nvolved in angiogenesis, inﬂammation and vascular remodeling
132].
.2. Ischemia and microRNAs
The formation of new blood vessels is an essential component
n pathologies such as ischemia, where interrupted blood ﬂow
eprives tissues of oxygen and nutrients necessary to maintain
heir normal functions. In ischemia, lack of oxygen, or hypoxia,
s associated with angiogenic stimuli (like expression of VEGF) in
n attempt for the cell to maintain tissue homeostasis [133]. In
esponse to ischemia, not only the expression of certain miRNAs
s increased, but their upregulation also modulates critical events
ssociated with ischemia-induced angiogenesis (Fig. 1A).ogical Research 75 (2013) 15– 27 19
MiR-210, also referred to as hypoxamir, is an intronic miRNA
contained within the sequence of the non-protein transcript
MIR210HG located on chromosome 11 [134] and its expression
is induced in hypoxic conditions in a hypoxia inducible factor-1
(HIF-1)-dependent manner. Fasanaro et al. showed that hypoxia-
induced miR-210 enhanced the development of capillary-like
structures and VEGF-induced chemotaxis in ECs [135]. Interest-
ingly, Hu et al. showed that miR-210 promoted angiogenesis and
inhibited apoptosis while improving cardiac function in a murine
model of myocardial infarction, suggesting that miR-210 might be
a promising therapy for ischemic disease [136]. This miRNA exerts
its pro-angiogenic and anti-apoptotic effects by downregulating
ephrinA3 (EFNA3) [135,136] and protein tyrosine phosphatase 1b
(PTPN1) [136]. Additionally, the expression of miR-210 is upre-
gulated in atherosclerotic plaques providing a link between this
miRNA and EC dysfunction in atherosclerosis [137].
Consistent with the notion of miR-16 being upregulated in
response to VEGF, Spinetti et al. reported that patients with crit-
ical limb ischemia showed higher levels of miR-16 and miR-15a
in proangiogenic circulating cells (PACs), which impair PACs func-
tions [138]. Moreover, Hullinger et al. showed that miR-15 is
an important regulator in cardiac ischemic injury using LNA-
anti-miR-15 in mice [139]. Notably, targeting of miR-15 reduced
infarct size, inhibited cardiac remodeling and enhanced cardiac
function in response to ischemic damage, proving that miR-
15 might be an interesting potential therapeutic target [139].
Recently, Yin et al. reported that the nuclear receptor, peroxi-
some proliferator-activated receptor  (PPAR)  binds directly to the
PPRE site in the miR-15 promoter region, repressing its expression
[140]. Interestingly, the levels of PPAR decreased upon oxygen-
glucose deprivation in cerebral vascular ECs, an ischemia like insult,
increasing EC apoptosis as well as necrotic cell death. In contrast,
the activation of PPAR inhibited the levels of miR-15 and sub-
sequently, increased Bcl2 protein levels resulting in a reduction
of caspase 3 activity, of Golgi fragmentation and of cell death
in mouse cerebral endothelium after ischemic insult in vitro and
in vivo [140]. Targeting miR-15 or pharmacological activation of
PPAR may  be a promising therapeutic option to induce apoptosis
in stroke-induced vascular damage.
A recent study on miR-503, whose seed region differs in a
nucleotide from the canonical seed sequence of the miR-16 family,
showed that the miRNA is upregulated in culture conditions mim-
icking diabetes mellitus and ischemia-associated starvation in ECs
[141]. MiR-503 decreased EC proliferation, migration and cord for-
mation by targeting cell division cycle 25 (CDC25A) and cyclin E1
(CCNE1). Furthermore, administration of anti-miR-503 improved
blood ﬂow recovery and angiogenesis in diabetic mice with limb
ischemia. All these data suggest that the regulation of miR-503
levels could be a therapeutic tool in diabetic patients [141].
Given the complex stimuli in hypoxia, the angiogenic function
of certain miRNAs differs compared to normoxia. For instance,
miR-424 promotes angiogenesis in hypoxic conditions [142].
Speciﬁcally, hypoxia increases the expression of miR-424 by PU.1-
dependent transactivation in ECs. MiR-424 was  shown to target
cullin 2 (CUL2), a scaffolding protein critical for the assembly of
the ubiquitin ligase system, which stabilizes HIF-1 resulting in
increased proliferation and migratory capabilities in ECs [142].
3.3. Endothelial progenitor cells and microRNAs
Improvement of neovascularization is a therapeutic option to
rescue tissue from critical ischemia [143]. In this regard, circu-
lating endothelial progenitor cells (EPCs) have been suggested
to play an important role in maintenance of vascular integrity.
Recent work also indicates that miRNAs play a critical role in EPC
biology (Fig. 1A). Indeed, Minami et al. showed an increase of
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iR-221/miR-222 in circulating EPCs isolated from patients with
oronary artery disease (CAD) or ischemic heart disease. Impor-
antly, the expression levels of miR-221/miR-222 and number of
PCs were negatively correlated in CAD patients. Notably, the
xpression of miR-221/miR-222 was reduced in EPCs isolated from
AD patients receiving long-term statin therapy whereas the num-
er of EPCs was increased [144]. Recently, a study showed that
iR-21 overexpression impaired angiogenesis in ECs and also in
 murine model of choroidal neovascularization by targeting the
hoGTPase Rhob [145]. According to this data, the overexpression
f miR-21 decreased proliferation and impaired EPC angiogenesis
y targeting high-mobility group A2 (Hmga2) in vitro and in vivo
146]. Interestingly, the endogenous nitric oxide synthase inhibitor,
symmetrical dimethylarginine (ADMA), which is increased in
atients with CAD, was shown to induce the expression of miR-
1 in angiogenic progenitor cells (APCs). This resulted in increased
eactive oxygen species concentrations and impaired nitric oxide
ioavailability through an indirect regulation of superoxide Dis-
utase 2 (SOD2) [147]. Additionally, high ADMA plasma levels
nd miR-21 expression are correlated in APCs from CAD patients,
mpairing their migration capacity. Conversely, inhibition of miR-
1 in APCs from CAD patients recovered migratory capacity of APCs,
uggesting that miR-21 antagonism might be a promising strategy
o improve dysfunctional APCs in patients with coronary artery dis-
ase [147]. However, other studies reported a pro-angiogenic role
f miR-21 in ECs [148] and tumors [149,150].
.4. Endothelial cell senescence and microRNAs
EC senescence plays an important role in the pathogenesis of
ascular dysfunction. Several miRNAs have been involved in this
rocess such as miR-217 [151] and miR-146 [152] (Fig. 1A). In
articular, Menghini et al. reported that miR-217 negatively reg-
lated the expression of silent information regulator 1 (SirT1),
 NAD+-dependent deacetylase, which prevented stress-induced
enescence and mediated angiogenesis through deacetylation of
he forkhead transcription factor (FoxO1). Indeed, overexpression
f miR-217 in young ECs induced a premature senescent-like phe-
otype and impaired angiogenesis whereas its inhibition in old ECs
educed senescence and increased angiogenesis [151]. On the other
and, aging, which is associated with an increase of reactive oxygen
pecies (ROS) and promotes senescence, decreases the expression
f miR-146 in ECs. In particular, Vasa-Nicotera et al. showed that
iR-146 negatively regulated the expression of NOX4, the main
ndothelial isoform of the NADPH oxidases complex [152]. There-
ore, overexpression of miR-146 might be a novel therapeutic tool
or vascular disorders by targeting the production of ROS and there-
ore regulating senescence [152].
. Control of leukocyte trafﬁcking and inﬂammation by
ndothelial microRNAs
Inﬂammation is an integral part of a wide array of human
iseases and it is an essential component of the innate immune
esponse to pathogens and damaged cells. Inﬂammation is usually
eﬁned as the local recruitment and activation of leukocytes
10,14]. In response to pathogens or inﬂammatory cytokines
ncluding IL-1 and TNF-, ECs get “activated” acquiring new
apacities, therefore controlling a multi-step process in which
eukocytes ﬁrst transiently tether to and roll on the EC surface,
hen adhere more strongly and migrate over the endothelium, and
nally squeeze between ECs to emigrate from the intravascular
pace to the extravascular sites of inﬂammation [153,154]. In
esting conditions, leukocytes do not interact with ECs, because
hey sequester the proteins responsible for the interaction withogical Research 75 (2013) 15– 27
leukocytes (e.g. P-selectin and chemokines) within secretory vesi-
cles known as Weibel–Palade bodies [155,156]. In these conditions
the expression of other adhesion molecules, such as E-selectin,
vascular cell-adhesion molecule 1 (VCAM1) and intracellular
adhesion molecule1 (ICAM1) is suppressed [157,158].
Recent studies have shown that inducible miRNAs also
contribute to the regulation of inﬂammation [159] (Fig. 1B). Specif-
ically, miR-155 and miR-146, as well as miR-132, miR-125b and
miR-9, have been shown to be induced in different cell types (e.g.
human lung alveolar epithelial cells, macrophages, neutrophils) by
a variety of proinﬂammatory stimuli such as IL-1, TNF, IFN, LPS and
Toll-like receptor (TLR) ligands [160–164]. In the context of ECs, in
addition to miR-155 (prototype of TNF-induced miRNA in different
cell types), TNF induces the expression of miR-31 and miR-17-3p,
among others. Interestingly, E-selectin (E-SELE) and ICAM1 were
identiﬁed and validated as targets of the TNF-induced miRNAs,
miR-31 and miR-17-3p, respectively [165]. Speciﬁc antagonism of
these TNF-induced miRNAs increased neutrophil adhesion to cul-
tured ECs. Conversely, transfections with mimics of these miRNAs
decreased neutrophil adhesion to ECs [165]. MiR-126, a constitu-
tively expressed, but EC-restricted miRNA, has also been involved in
vascular inﬂammation by modulating VCAM-1 expression induced
by TNF [81]. However, the expression of this miRNA was affected
by TNF treatment [165]. In response to TNF the expression of miR-
181b has been shown to be reduced in ECs. MiR-181b regulates the
expression of importin-3  (KPNA4), a protein required for nuclear
translocation of NF-kB. As activation of the transcription factor NF-
kB is critical for TNF-induced inﬂammatory responses, miR-181b
has been shown to indirectly decrease NF-kB responsive genes,
such as VCAM1 and SELE in ECs in vitro and in vivo [166]. Impor-
tantly, the overexpression of miR-181b by intravenous delivery
reduced the NF-kB pathway and decreased lung injury and mor-
tality in endotoxemic mice while the endogenous inhibition of
miR-181b increased the inﬂammatory phenotype. Consistent with
this, the expression of miR-181b is reduced in patients critically ill
with sepsis [166]. Altogether, these data suggest that the overex-
pression of miR-31, miR-17-3p, miR-126 and miR-181b could be an
important tool for anti-inﬂammatory therapy in several patholog-
ical conditions including atherosclerosis and rheumatoid arthritis
among others.
MiR-10a has been reported to negatively regulate the NF-
kB pathway by targeting mitogen-activated kinase kinase kinase
7 (MAP3K7) and -transducin repeat containing gene (TRC),
two regulators of the proteosomal degradation of IkB and p65
translocation in ECs [167]. Interestingly, the expression of miR-
10a is decreased in athero-susceptible arterial regions while the
expression of MAP3K7 and TRC is upregulated, suggesting that
the differential expression of miR-10a could contribute to the
regulation of pro-inﬂammatory endothelial phenotypes in athero-
susceptible regions [167].
Angiotensin II (Ang II) can induce the expression of different
adhesion molecules and therefore initiate the vascular inﬂam-
matory response. A recent study showed that miR-155 and
miR-221/222 negatively regulated Ets-1 [132], a key transcription
factor of endothelial inﬂammation and angiogenesis. Interestingly,
in Ang II stimulated ECs, Ets-1 and several of its downstream genes
include VCAM1, MCP1 and FLT1 were upregulated. This effect was
partially reversed by overexpression of miR-155 or miR-221/222.
In particular, the overexpression of miR-155 and miR-221/222
reduced leukocyte adhesion to ECs, as well as EC migration
[132].
Oxidized Low Density Lipoproteins (Ox-LDL) are known to
enhance the expression of pro-inﬂammatory genes, leading to
monocyte recruitment into the vessel wall and dysfunction of
vascular ECs [168]. MiR-125a/b are highly expressed in vascu-
lar ECs and their expression can be modulated by ox-LDL [169].
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x-LDL-induced apoptosis in ECs is thought to play a criti-
al role in atherosclerosis. Interestingly, miR-365 expression is
egulated by ox-LDL in ECs and potentiates ox-LDL-mediated apo-
tosis by regulating the expression of Bcl-2 [170]. Atherosclerotic
esions preferentially originate and develop at arterial sites of
urvatures, branches, and bifurcations where complex hemody-
amic conditions of disturbed ﬂow are associated with endothelial
henotypes expressing proinﬂammatory and procoagulant sus-
eptibility [171]. The NF-B signal transduction pathway has
een shown to be primed for activation in regions predisposed
o atherosclerotic lesion formation. Conversely, KLF2, KLF4, and
uclear factor erythroid 2–like 2 regulate gene networks that confer
theroprotective properties to the endothelium through an anti-
nﬂammatory/antioxidant and anticoagulant phenotype proﬁle.
ang et al. reported that the upregulation of miR-92a expression
nversely correlated with KLF2 and KLF4 expression in athero-
usceptible endothelium [172]. Indeed, miR-92 decreased KLF2 and
LF4 expression and knockdown of miR-92a partially suppressed
NF-induced endothelial inﬂammatory mediators through KLF4
nd KLF2, therefore inhibiting TNF-induced leukocyte adhesion to
Cs in vitro [172].
Gene expression proﬁles are dramatically altered when ECs are
xposed to laminar shear (LS) or oscillatory shear (OS) stress. LS
s known to increase expression of atheroprotective genes includ-
ng KLF2, KLF4 and eNOS, while OS stimulates inﬂammation by
verexpression of bone morphogenic protein-4 (BMP4) and adhe-
ion molecules [171,173–175]. MiRNA microarray analysis of ECs
xposed to OS or LS identiﬁed 21 miRNAs differentially expressed,
ncluding miR-663, which was found to be upregulated in OS.
reatment of ECs with the miR-663 antagonist blocked OS-induced
onocyte adhesion, but not apoptosis. In contrast, overexpress-
on of miR-663 increased monocyte adhesion in LS-exposed cells.
otential miR-663 targets included a network of inﬂammatory
enes and transcription factors such as KLF4 [176].
. Control of barrier function by endothelial microRNAs
ECs form a monolayer, within the blood vessel, by which the
ells are linked to each other by different types of adhesive struc-
ures or cell-cell junctions (i.e. tight junctions, adherens junctions
nd gap junctions). This permits a selective barrier to form for the
ransport of molecules between blood and tissues [177,178]. These
dhesive structures, which are involved in the control of the vas-
ular permeability to circulating cells, also needs to be regulated
n coordination with the functional requirements of the irrigated
rgan [179]. Changes in endothelial permeability are associated
ith redistribution of surface cadherins or occludins, stabilization
f focal adhesion bonds and the progressive activation of matrix
etalloproteases [180]. Loss of barrier function in pathophysiolo-
ical situations can lead to extracellular edema. Different stimuli,
uch as histamine and thrombin, induce a rapid and short-lived
ncrease in vascular permeability while others, like TNF or VEGF,
nduced a more sustained response. Of interest, most of these ago-
ists are produced in situations of acute or chronic inﬂammation
181]. Recent work also indicates that miRNAs play an important
ole in controlling barrier function as described below and depicted
n Fig. 1C.
MiR-125b expression has been shown to be transiently induced
n ECs stimulated with VEGF. This miRNA inhibited the translation
f vascular endothelial (VE)-cadherin mRNA. Because miR-125b
nduction in ECs is transient after VEGF stimulation, prolonged
verexpression of miR-125b could result in blood vessel regression
ue to loss of normal barrier function [181].
Hantaviruses infect human ECs and cause two diseases marked
y vascular permeability defects, hemorrhagic fever with renalogical Research 75 (2013) 15– 27 21
syndrome (HFRS) and hantavirus pulmonary syndrome (HPS)
[182]. Vascular permeability occurs in the absence of EC lysis,
suggesting that hantaviruses alter normal EC ﬂuid barrier func-
tions [182]. Andes hantavirus (ANDV) infection of human ECs
results in changes in the level of speciﬁc EC miRNAs, including
miR-155, miR-320, and miR-222 [182]. These miRNAs reportedly
regulate adherens junction disassembly, cell migration, and cell
morphology, which contribute to changes in vascular perme-
ability [61,62,183]. However, other miRNAs were downregulated
3–3400-fold following ANDV infection; these included miR-410,
involved in regulating secretion, and miR-218, which is linked to
the regulation of EC migration and vascular permeability [182].
In particular, this ﬁnding suggests that in ANDV-infected ECs
decreased miR-218 levels may  enhance VEGF-directed permeabil-
ity by increasing Robo1 and thereby decreasing Robo4 regulation.
Robo4 normally stabilizes the vasculature by counteracting VEGF
signaling responses that result in EC hyperpermeability [184,185].
The changes in miR-126, an EC-speciﬁc miRNA that regulates vas-
cular integrity by suppressing SPRED1 and PIK3R2 mRNAs [87,89],
were also analyzed [182]. While miR-126 levels were only slightly
altered, SPRED1 and PIK3R2 mRNA levels were increased 10- and
7-fold, respectively, in ANDV-infected ECs but were unaltered in
ECs infected by the nonpathogenic Tula hantavirus. Consistent
with increased SPRED1 expression, the level of phospho-coﬁlin
was decreased within ANDV-infected ECs, therefore enhancing
adherens junction disassembly responses [182].
6. Control of vascular tone by endothelial microRNAS
ECs control the secretion of two potent short-lived mediators
that inﬂuence vascular hemodynamics in the physiological state
and therefore contribute to the regulation of blood pressure and
blood ﬂow by releasing vasodilators, such as NO and prostacyclin or
prostagladin I2 (PGI2), as well as vasoconstrictors, including ET and
platelet activating factor (PAF) [4]. The speciﬁc blood-mediators
released by ECs vary depending on the vascular bed, but the princi-
pal vasorelaxant is NO [9]. NO is generated in ECs by the oxidation
of l-Arginine to l-Cytruline by eNOS [186,187]. eNOS is a consti-
tutively expressed gene that can be upregulated by increases in
shear stress of growth factors, such as VEGF and some drugs, includ-
ing 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
(statins). Conversely, hypoxia, lipopolysaccharide (LPS), TNF and
ox-LDL decrease its expression [188]. In addition, eNOS function is
also tightly regulated by its subcellular localization, protein-protein
interactions and multi-site phosphorylation mostly by the protein
kinases AKT and AMPK [186,189]. Regarding the role of miRNAs
in regulating vascular tone (Fig. 1C), initial studies, showed that
knockdown of Dicer, the enzyme necessary for miRNA maturation,
increased eNOS expression in ECs [77]. Transfection of miR-221 and
miR-222 mimics partially reversed the increases of eNOS protein
attributable to Dicer silencing, suggesting miR-221 and miR-222
may  be involved in the control of eNOS expression. However, the
effect of these miRNAs on eNOS might be indirect since no pre-
dicted binding sites have been found in the eNOS 3′UTR [77].
Recent reports indeed provide evidence that miR-155 downreg-
ulated eNOS expression through decreasing eNOS mRNA stability
by binding to its 3′-UTR [190]. Interestingly, TNF increased miR-
155 expression in ECs [165] and knockdown of miR-155 prevented
cytokine-induced downregulation of eNOS expression, reduction of
NO production, and impairment of endothelium-dependent vascu-
lar relaxation [190]. Moreover, the authors found that simvastatin
ameliorated TNF-induced endothelial dysfunction via inhibition of
miR-155 expression [190].
NO has pleiotropic effects on the vasculature. It causes vas-
cular smooth muscle cell (SMC) relaxation, which maintains
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asomotor tone, inhibits SMC  migration and proliferation and pre-
ents platelet and leukocyte activation and adhesion [4,191–193].
ailure of ECs to control these basal functions constitutes “EC
ysfunction” leading to vessel constriction, thrombosis and
nﬂammation. Local disturbances in blood ﬂow trigger these
ndesired effects and explain why regions with disturbed ﬂow,
uch as arterial branch points, have diminished NO secretion and
re prone to develop atheromas [194]. Several reports showed that
hear stress induced the expression of miR-21 with contrasting
ffects. In particular, laminar ﬂow increased miR-21 and reduced
poptosis and increased nitric oxide (NO) production by modu-
ating The PI3K/Akt pathway, overall ameliorating EC functions
195]. However, Zhou et al. reported that OS increased miR-21
xpression, which repressed peroxisome proliferators-activated
eceptor- (PPAR),  a repressor of activator protein-1 (AP-1)
ignaling. In particular, AP-1 induced the expression of different
dhesion molecules and miR-21 itself. These data showed that
S-induced miR-21 promoted endothelial inﬂammation [196].
hese controversial ﬁndings might be explained by the difference
n cellular context and, likely, also in the magnitude of upregulation
f miR-21 induced by laminar or oscillatory shear stress.
In addition to producing the potent vasodilator NO, ECs also
ynthesize endothelin-1 (ET-1), one of the most potent vasocon-
trictors [197]. ET-1 expression and secretion by ECs is stimulated
y hypoxia, shear stress and ischemia. Upon release, it binds to the
-coupled ET-A receptor on vascular SMCs, resulting in an increase
n calcium concentration and vascular SMC  tone. NO controls the
uration of these effects by accelerating the restoration of intra-
ellular basal calcium levels. Therefore, in states of EC dysfunction,
uch as atherosclerosis, where NO levels are reduced, ET-1 pro-
otes vasoconstriction and SMC  proliferation [198]. MiR-125a/b
as been involved in the regulation of the potent vasoconstric-
or ET-1. Interestingly, an inverse correlation between the levels of
iR-125a/b and the precursor protein ET-1 (preproET-1) has been
eported in aortas in stroke-prone spontaneously hypertensive rats
ompared to normotensive rats [169]. Due to the relevance of ET-
 in many vascular diseases such as hypertension, atherosclerosis
nd stroke, targeting of miR-125a/b could provide an important
herapeutic approach.
. Control of endothelial cell functions by secreted
icroRNAs
MiRNAs are not only important as cell autonomous modulators
f cellular functions, but also in light of their role as mediators of
aracrine cell-to-cell communication [199]. Cells can communicate
ith other cells via multiple mechanisms. Besides passive protein
nd RNA shedding, cytokines, chemokines, enzymes or hormone
ecretion, they can release miRNA-protein complexes, lipoproteins
ontaining miRNAs and vesicular particles that contain proteins
nd RNAs in the extracellular milieu [199].
Increasing evidence has demonstrated that many cell types are
ble to secrete extracellular microvesicles into the extracellular
pace that can be uptaken by other cells [200]. Since microvesicles
etain surface receptors and ligands typical of their cells of origin,
hey might preferentially deliver their content to certain cell types.
ecause of the speciﬁcity of their content and of their potential
argets, microvesicles can be both markers and mediators of
isease [200].
The population of microvesicles is heterogeneous and includes
esicles from different origins. Although the classiﬁcation of extra-
ellular vesicles is still a matter of debate, it is well accepted to
istinguish them based on the cellular process that they originate
rom [201].
Apoptotic bodies are large vesicles secreted by apoptotic cells
nd are heterogeneous in size and composition. Usually apoptoticogical Research 75 (2013) 15– 27
bodies are identiﬁed as vesicles of 50–500 nm in diameter [202].
Shedding microvesicles have a diameter of 100–1000 nm and are
produced by budding from the extracellular membrane and con-
tain proteins and nucleic acids. Exosomes are around 30–100 nm
in diameter and are produced within the endosomal compartment
into multivesicular bodies. Exosomes are identiﬁed by the presence
of tetraspanins (CD63, CD9, CD81) as well as endosomal proteins,
such as Alix and Tsg101. They contain RNAs, especially miRNAs,
which can be delivered to target cells. Interestingly, exosome pro-
tein and RNA composition depends on the activation status of the
cell of origin [203], but it does not mirror its composition, as some
miRNAs are speciﬁcally enriched in exosomes and not in cells. Exo-
somal proteins might be able to target exosomes to speciﬁc cells
that have cognate membrane proteins [204].
ECs can both produce extracellular vesicles that target other
cells and modify their function, or they can be targets of extra-
cellular vesicles derived from other cells (Fig. 1D).
Human monocytes can secrete microvesicles containing miR-
NAs that are uptaken by ECs and increase their migratory
capabilities. MiR-150 is contained in monocyte-derived microvesi-
cles, both from the monocytic cell line, THP1, and from human
peripheral blood monocytes [205]. The miRNA can be transferred
to ECs and induce downregulation of c-Myb, which is responsible
for the increased migratory capabilities of ECs. Moreover, patients
with severe atherosclerosis had circulating microvesicles that were
enriched in miR-150 compared to control patients, suggesting that
their microvesicles might be either partially responsible for the
vascularization of atherosclerotic plaques or might be a marker
of it, since they have a higher monocyte inﬁltration in the lesion
[205].
Tumor cells have been shown to produce large amounts of
microvesicles. Several reports show that microvesicles have a pos-
itive effect on tumor development, by targeting, immune cells and
ECs, among others [206,207].
Recent works have provided evidence that cancer-derived
microvesicles can regulate EC functions. Cancer stem cells (SCs)
have the capacity to initiate tumors from single cells. They are
CD105+ cells and can give rise to cells of multiple lineages, like
epithelial cells and ECs. Cancer SCs can produce microvesicles
that are characterized by the surface expression marker CD105
and, have the ability to prepare the microenvironment to promote
tumor growth and angiogenesis. In particular, CD105 microvesi-
cles display enrichment in certain miRNAs, whose main targets
are involved in crucial biological processes and likely angiogenesis
[207].
Zhuang et al. described that the ability of different tumor cell
lines (lung cancer, pancreatic cancer, melanoma, glioblastoma,
colorectal cancer) to modify EC functions is through microvesicle-
derived miRNAs. Among the miRNAs transferred by tumors
through microvesicles, they identiﬁed miR-9, which activates
the JAK/STAT pathway by downregulating suppressor of cytokine
signaling 5 (SOCS5) to induce EC migration [208].
Apoptotic bodies produced by ECs during atherosclerosis con-
tain miRNA-126. By targeting the regulator of G protein signaling
16 (Rgs16), an inhibitor of G protein-coupled receptor signaling
(GPCR), miR-126 increases the expression of chemokine receptor
type 4 (CXCR4), which in turn increases chemokine receptor type 12
(CXCL12) that counteracts apoptosis and recruits progenitor cells
in mice with atherosclerosis [209].
EPCs are believed to exert a protective effect in many dis-
ease models. It is well accepted that EPCs can secrete paracrine
protective factors, but recent studies have shed light on the impor-
tant role of EPC-derived microvesicles and their miRNA cargo.
In fact, the regenerative effects of EPCs in a model of ischemia-
reperfusion injury in the kidney as well as hind limb ischemia have
also been attributed to EPCs ability to secrete miRNA-containing
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icrovesicles, and speciﬁcally miR-126 and miR-296-rich vesicles
210,211]. Those microvesicles could improve capillary rarefaction,
lomerulosclerosis and tubulointerstitial ﬁbrosis in kidney injury
nd increase capillary density in ischemia. Importantly, the ability
f microvesicles to produce a phenotype was lost after treatment
ith RNase or if they were deprived of miRNAs by silencing of Dicer
210,211].
Upon shear stress, ECs can secrete microvesicles that are able
o mediate an atheroprotective effect on vascular SMCs. Hergen-
eider et al. induced the production of microvesicles from ECs
verexpressing the shear-responsive gene KLF2 or under shear
tress. Those microvesicles were enriched in miRNAs, particularly
iR-143/145, that mediated an atheroprotective action on smooth
uscle cells [212]. Similarly, delivery of miR-143/145-enriched
esicles in ApoE−/− mice fed a high fat diet induced an athero-
rotective effect, which was reverted if the microvesicles were
epleted of miR-143/145.
Several studies also identiﬁed miRNAs in plasma or serum as
iomarkers in certain diseases associated with EC function (Fig. 1D).
lood miRNAs are extremely stable to freeze/thaw cycles and
NAse treatment, raising the possibility that these miRNAs could
e derived from circulating microvesicles produced by damaged
ells [213,214].
Fichtlscherer et al. identiﬁed miRNAs dysregulated in patients
ith coronary artery disease [215]. In particular they found that
iR-126, miR-155, and miR-145 were signiﬁcantly reduced in
atients with CAD and diabetes, while miR-17 and miR-92a were
ownregulated only in CAD patients. However, the origin and func-
ional signiﬁcance of these circulating miRNAs needs to be further
xplored.
Type 2 diabetes critically affects some EC functions and impairs
ostischemic reparative neovascularization. Therefore the study
f miRNAs that are both markers and potential therapeutic
reatments is of pivotal importance. Zampetaki et al. analyzed
icrovesicles from patients with type 2 diabetes and conﬁrmed
he downregulation of miR-126, as well as of other miRNAs, and
mong them miR-15a, miR-29b, miR-223, which were associated
ith an incidence of diabetes mellitus over 10-years [216]. Inter-
stingly, miR-126 abundance in microvesicles produced by ECs
reated with high glucose was also decreased compared to con-
rols, suggesting an endothelial origin of the miR-126-depleted
icrovesicles in diabetic patients that also contribute to EC dys-
unction.
In patients with diabetes-induced critical limb ischemia, a
iRNA critical in EC function was found to be upregulated in the
lasma of patients compared to controls, as well as in their muscles.
igh D-glucose treatment of ECs, which mimics diabetic condi-
ions, induces the increase in expression of miR-503. This miRNA
n turn decreases the angiogenic properties of ECs through repres-
ion of cdc25A and CCNE1 (as described above) [141]. Moreover,
he anti-angiogenic miR-15 and miR-16 were found to be upregu-
ated in patients with critical limb ischemia, without correlations
ith type 2 diabetes, further suggesting that circulating miRNAs
n diabetes might promote the anti-angiogenic phenotype of ECs
138].
A  note of caution should be addressed on the issue of detec-
ing secreted miRNAs in patients. It is well known that diseases
rofoundly change the miRNA expression in cells. Furthermore,
athologies change the rate of release of miRNAs from different
issues, as well as their stability, profoundly affecting the abun-
ance of miRNAs or other RNAs that are normally used as controls in
ealthy patients. Therefore common qPCR techniques that involve
he normalization of the target miRNA relative expression with
ontrol-unchanged miRNAs should be analyzed carefully. Similarly,
ack of a normalization control is also an issue for the quantiﬁcation
f microvesicle-derived miRNAs.ogical Research 75 (2013) 15– 27 23
8. Pharmacological potential of microRNAs for endothelial
cell dysfunction
Tissue speciﬁcity and the capability of coherently targeting mul-
tiple pathways are features that make miRNAs research targets of
valuable therapeutic interest.
MiRNAs could be inhibited, exploiting chemically stable com-
plimentary oligonucleotides [217], or their activity mimicked with
so-called mimics [218]. Inhibition of miRNAs might be achieved by
chemically stabilized 2′-O-methyl oligonucleotides (or anti-miRs)
complimentary to the miRNA of interest [217]. Anti-miRs were ﬁrst
shown to be effective in Drosophila melanogaster and Caenorhab-
ditis elegans, where they were used to inhibit let-7 [217]. It is
believed that anti-miRs irreversibly bind to the complementary
target miRNA and block their processing by the miRISC complex,
however the mechanism has not been fully investigated [218,219].
Linking 2′-O-methyl anti-miRs with cholesterol, a process to
generate the so-called antago-miRs, increases the cellular uptake
and bioavailability in larger animals and their action has been
shown to last up to 23 days when delivered by tail vein injection
in mice and target most tissues [220]. The effects of anti-miRs and
antago-miRs have mostly been elucidated in rodents and only a
few reports have extended their studies on animal models closer
to humans. For example, miR-33 inhibition by anti-miR in non-
human primate African green monkeys was reported to be effective
in increasing HDL plasma levels by upregulation of hepatic ABCA1
[221]. In addition to anti-miRs and antagomiRs, LNA-modiﬁed
phosphorothioate oligonucleotide DNAs have been developed to
inhibit miRNAs in vitro, as well as in vivo [222,223]. Of note, the
therapeutic long-lasting efﬁcacy of LNA-anti-miRs against the liver-
speciﬁc miR-122 has been demonstrated in African green monkeys,
as well as chimpanzees, to decrease plasma cholesterol levels and to
prevent replication of the hepatitis C virus (HCV) [224,225]. A clin-
ical trial of LNA-anti-miR-122, called miravirsen, on HCV patients
is now in Phase IIa and has so far established the safety, as well the
efﬁcacy, of miravirsen in inhibiting HCV disease progression.
Delivery of a high number of miRNA target sequences that decoy
binding sites and reduce the availability of the target miRNA, a
strategy called ‘sponging’, has proven to be effective in knocking
down the functionality of miRNAs. Successful sponging of miRNAs
in vivo was ﬁrst reported in bone marrow derived cells that were
transduced with lentiviral particle encoding for miR-223 targets
and could reconstitute the hematopoietic system of receiving mice
[226].
Even though sponging of miRNAs has been successful in mouse
models, it has some limitation due to the nature of genetic mate-
rial transferred, usually bulky plasmids delivered by viral vectors
[227]. On the other hand, oligonucleotide-based inhibition is more
promising in the light of potential future chemical improvements
that might generate more readily delivered, targeted and long-
lasting oligonucleotide inhibitors.
The opposite strategy of mimicking miRNA function has been
proven to be effective in vivo in various experimental conditions.
For example, delivery of miR-16 mimics, which is an anti-oncogenic
and anti-angiogenic miRNA as discussed above, suppresses the
progression of tumors [228]. Even though studies of miRNA inhi-
bition and overexpression in vivo do not report any long-lasting
side effect, it should be kept in mind that miRNA are able to tar-
get multiple pathways and generate important off-target effects
that could profoundly affect vital cellular functions. Additionally,
miRNA targets are not always conserved among species and there-
fore off-target effects that are not present in other animals might
represent a signiﬁcant problem in humans. Therefore the action of
therapeutically interestingly miRNAs has to be extensively investi-
gated in vitro and in vivo, not only in rodents but also in higher-order
animals like non-human primates, to conﬁrm the speciﬁcity of
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iRNA interaction with its targets and exclude side effects. Over-
ll, the successful studies in rodents and non-human primates, as
ell as the preliminary results on clinical trials, show that miRNA
nhibition and overexpression is a promising therapeutic tool in
iseases and hopefully it will pave the way to human clinical trials
f angiogenic/anti-angiogenic miRNAs to cure vascular diseases.
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